Skip to content

Effects of Ameining on liver function: an open-label, outpatient, real-world study

Effects of Ameining on liver function: an open-label, outpatient, real-world study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075209
Enrollment
Unknown
Registered
2023-08-29
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive disorder

Interventions

Case group (Ameining ):None

Sponsors

Chaohu Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 65 Years

Inclusion criteria

Inclusion criteria: a) Age 13-65 years old, regardless of gender; b) meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition) diagnostic criteria for depression, anxiety, sleep disorders, somatic symptoms, and related disorders, and do not have psychotic symptoms; c) Pregnancy test (urine) results for women of childbearing age were negative at screening and baseline. Male and female subjects of reproductive age agree to use effective contraception throughout the study period and for at least 28 days after their last dose of the trial drug; d) Primary school education and above; e) Understand the study content, be willing to participate in the study, and sign a written informed consent.

Exclusion criteria

Exclusion criteria: a) have other major mental disorders that meet the DSM-5 diagnostic criteria, including organic mental disorders, alcohol dependence, drug dependence/abuse, schizophrenia, bipolar disorder, etc.; b) Allergic or known agomelatine allergy; c) Patients with known chronic hepatitis with abnormal ALT and AST at baseline screening; d) History of drug abuse; e) In the investigator's judgment, there is a clear and present risk of suicide or violent behavior; f) The patient is currently accompanied by definite hallucinations, delusions and other psychiatric symptoms, using any of the positive symptom items of the Concise Psychiatric Rating Scale (BPRS) (including hallucinations, exaggerations, suspicions, and unusual thinking content) > 1 point; g) Positive urine toxicology screening at screening or baseline; h) Previous organic brain lesions or severe external injuries to the brain; i) Patients with serious heart, liver and renal insufficiency, metabolic diseases and other serious physical diseases; j) Women who are pregnant or breastfeeding; k) Failure to provide informed consent.

Design outcomes

Primary

MeasureTime frame
ALT;AST;

Secondary

MeasureTime frame
HAMD;Hamilton anxiety scale;Pittsburgh sleep quality index;

Countries

China

Contacts

Public ContactKai Zhang

Chaohu Hospital of Anhui Medical University

zhangkai@ahmu.edu.cn+86 551 8232 4114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026